Optase, a prescription product formulated in a patent-pending gel delivery system for topical application, promotes healing in the treatment of decubitus ulcers, varicose ulcers and dehiscent wounds. Eloquest Healthcare will market Optase in the acute care setting. Optase is one of two products that the companies are co-promoting.
“Partnering with Onset on this venture makes good business sense,” says Tim O'Halla, Vice President and Chief Operating Officer, Eloquest Healthcare. “Optase is just the right type of product to help us further or mission of providing healthcare professionals and patients with valued and trusted service, specialized products, and expertise that engender compassionate care.”
Crysta Seneski, Associate Director of Marketing, Eloquest Healthcare states “Adding Optase to our product mix allows us to expand our topical capabilities, and provides us with entry into a new market of wound care management.”
The optimized gel formulation found in Optase contains active ingredients that not only protect the wound, but also increase capillary blood flow to promote healing. The transparent, gel formulation is almost colorless, which allows for improved visualization and evaluation of the wound. The lower viscosity of Optase Gel allows the product to be easily dispensed and spread onto the wound with minimal disruption to the wound bed during application. Optase Gel also helps to maintain a moist wound healing environment, protects wounds from external moisture and debris, and promotes autolytic debridement.
Another Optase advantage is in its easy-to-use flip top squeeze bottle packaging that allows for a more convenient and safer product application with one hand. With Optase there is minimal risk of losing or contaminating the cap, which can occur with other package configurations that include a separate cap. In addition, with 37% more volume per unit than most competitors, use of Optase may reduce the number of units dispensed per patient.
“Since launching our company in early 2008, we have been working with our customers to pursue a common goal of delivering excellence in healthcare, always with a measure of compassion,” O'Halla says. “We plan to continue achieving this goal by establishing partnerships with like-minded companies, such as Onset Therapeutics, and also through the acquisition and/or development of unique products.”
He adds, “With our strong sales force infrastructure and established resources already in place, we're strategically positioned to market this product effectively, making this a win-win for both companies.”
“Partnering with Onset on this venture makes good business sense,” says Tim O'Halla, Vice President and Chief Operating Officer, Eloquest Healthcare. “Optase is just the right type of product to help us further or mission of providing healthcare professionals and patients with valued and trusted service, specialized products, and expertise that engender compassionate care.”
Crysta Seneski, Associate Director of Marketing, Eloquest Healthcare states “Adding Optase to our product mix allows us to expand our topical capabilities, and provides us with entry into a new market of wound care management.”
The optimized gel formulation found in Optase contains active ingredients that not only protect the wound, but also increase capillary blood flow to promote healing. The transparent, gel formulation is almost colorless, which allows for improved visualization and evaluation of the wound. The lower viscosity of Optase Gel allows the product to be easily dispensed and spread onto the wound with minimal disruption to the wound bed during application. Optase Gel also helps to maintain a moist wound healing environment, protects wounds from external moisture and debris, and promotes autolytic debridement.
Another Optase advantage is in its easy-to-use flip top squeeze bottle packaging that allows for a more convenient and safer product application with one hand. With Optase there is minimal risk of losing or contaminating the cap, which can occur with other package configurations that include a separate cap. In addition, with 37% more volume per unit than most competitors, use of Optase may reduce the number of units dispensed per patient.
“Since launching our company in early 2008, we have been working with our customers to pursue a common goal of delivering excellence in healthcare, always with a measure of compassion,” O'Halla says. “We plan to continue achieving this goal by establishing partnerships with like-minded companies, such as Onset Therapeutics, and also through the acquisition and/or development of unique products.”
He adds, “With our strong sales force infrastructure and established resources already in place, we're strategically positioned to market this product effectively, making this a win-win for both companies.”
Companies in this article
